Why the study?
Does LVAD support alter transcriptomic signatures in end-stage human dilated cardiomyopathy hearts?
Does LVAD support alter transcriptomic signatures in end-stage human dilated cardiomyopathy hearts?
LVAD support induces chamber-specific transcriptomic changes, including improvements in immune response and ECM remodeling genes, contributing to reverse ventricular remodeling in end-stage dilated cardiomyopathy.
Answers are grounded in this paper and cite their sources.
LVAD-induced transcriptomic shifts in DCM may support reverse remodeling; hypothesis-generating and requires outcome validation before clinical relevance.
= 6). Gene expression (for mRNAs/miRNAs) was determined using microarrays. Our results demonstrate that immune response, oxygen homeostasis, and cellular physiological processes were the most enriched pathways among differentially expressed genes in both ventricles of end-stage DCM hearts. LV genes involved in circadian rhythm, muscle contraction, cellular hypertrophy, and extracellular matrix (ECM) remodelling were differentially expressed. In the RV, genes related to the apelin signalling pathway were affected. Following LVAD use, immune response genes improved in both ventricles; oxygen homeostasis and ECM remodelling genes improved in the LV and, four miRNAs normalized. We conclude that LVAD reduced the expression and induced additional transcriptomic changes of various mRNAs and miRNAs as an integral component of the reverse ventricular remodelling in a chamber-specific manner.
No takes yet. Share an insight, caveat, or question.
Parikh et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: